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Abstract
Pediatric cancer is a relatively rare and heterogeneous group of hematological and non-hematological malignancies which
require multiple procedures for its diagnostic screening and classification. Until now, flow cytometry (FC) has not been
systematically applied to the diagnostic work-up of such malignancies, particularly for solid tumors. Here we evaluated a FC
panel of markers for the diagnostic screening of pediatric cancer and further classification of pediatric solid tumors. The
proposed strategy aims at the differential diagnosis between tumoral vs. reactive samples, and hematological vs. non-
hematological malignancies, and the subclassification of solid tumors. In total, 52 samples from 40 patients suspicious of
containing tumor cells were analyzed by FC in parallel to conventional diagnostic procedures. The overall concordance rate
between both approaches was of 96% (50/52 diagnostic samples), with 100% agreement for all reactive/inflammatory and
non-infiltrated samples as well as for those corresponding to solid tumors (n = 35), with only two false negative cases
diagnosed with Hodgkin lymphoma and anaplastic lymphoma, respectively. Moreover, clear discrimination between
samples infiltrated by hematopoietic vs. non-hematopoietic tumor cells was systematically achieved. Distinct subtypes of
solid tumors showed different protein expression profiles, allowing for the differential diagnosis of neuroblastoma (CD56hi/
GD2+/CD81hi), primitive neuroectodermal tumors (CD271hi/CD99+), Wilms tumors (.1 cell population), rhabdomyosarcoma
(nuMYOD1
+/numyogenin
+), carcinomas (CD452/EpCAM+), germ cell tumors (CD56+/CD452/NG2+/CD10+) and eventually also
hemangiopericytomas (CD452/CD34+). In summary, our results show that multiparameter FC provides fast and useful
complementary data to routine histopathology for the diagnostic screening and classification of pediatric cancer.
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Introduction
More than 200,000 pediatric patients (,15 years old) are
diagnosed with cancer every year [1]. Despite cancer is the leading
cause of disease-related death in children in most countries [2],
individual outcomes largely depend on fast tumor diagnosis,
classification and staging, for appropriate therapy selection and
maximized cure rates [3]. Since a significant proportion of
pediatric tumors lack morphological evidence of differentiation
and histological origin, a battery of immunocytochemical markers
and in situ hybridization, ultrastructural and molecular diagnostic
procedures, are typically required for the diagnostic classification
of the disease [3–7].
For several decades, multiparameter flow cytometry (MFC)
immunophenotyping has proven to be essential for rapid
diagnosis, classification and monitoring of therapy of most
hematological malignancies, including pediatric leukemias and
lymphomas. Conversely, it remains a research tool for pediatric
solid tumors [8–15]. Such limited usage of MFC in the diagnosis of
pediatric solid tumors probably relates to the need for single cell
suspensions and the availability of relatively restricted panels of
reliable and validated markers, among other factors [16–18].
Thus, usage of flow cytometry in pediatric solid tumors has been
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almost restricted to the evaluation of tumor cell DNA contents in
both paraffin-embedded and frozen tissue specimens, in combi-
nation or not with simultaneous staining for one or a few
phenotypic markers [19–24]. Consequently, while immunophe-
notypic studies are routinely applied in most pediatric lymphomas
for the differential diagnosis between B- and T-cell precursor
lymphoblastic lymphomas and Burkitt lymphoma [25–28], few
studies have been reported so far, in which MFC is systematically
applied to the study of the phenotypic characteristics of pediatric
solid tumors [29–31]. In addition, the few reported studies have
mainly focused on descriptive analyses of the staining patterns for
one or a few markers, usually in a single diagnostic subtype of the
disease.
Despite all the above, preliminary studies have shown that
neuroendocrine tumors display a CD452/CD56+ phenotype [32–
35]; in turn, tumor cells from neuroblastoma coexpress GD2 [35],
whereas primitive neuroectodermal tumors (PNET) coexpress
CD57 and CD99, as well as CD56 [31,34,36–38], and rhabdo-
myosarcoma tumor cells are myogenin+ [31,39–41]. Despite this,
the specificity of these phenotypes among the distinct subtypes of
pediatric solid tumors remains to be established, and no study has
been reported so far, in which a comprehensive panel of markers
aimed at diagnostic screening, differential diagnosis and classifi-
cation of distinct types of pediatric tumors, has been proposed and
evaluated.
Here we evaluated a new comprehensive MFC panel of markers
for the diagnostic screening of pediatric cancer and correct
assignment of pediatric solid tumors to specific disease entities.
Materials and Methods
Patients and Samples
A total of 52 samples from 40 patients suspicious of pediatric
cancer –21 males (52.5%) and 19 females (47.5%) - were collected
between November 2009 and December 2011, at three distinct
centers: Instituto de Puericultura e Pediatria Martaga˜o Gesteira/
Universidade Federal do Rio de Janeiro (IPPMG/UFRJ) and
Hospital Servidores do Estado (HSE), both from Rio de Janeiro
(Brazil), and Hospital de Clı´nicas/Universidade Federal do Parana´
(HC/UFPR) in Curitiba (Brazil). Median patient age was of 5
years (range: 1–14 years). Most samples (48/52; 92.3%) were
analyzed at diagnosis.
In all cases, final diagnosis and classification was established
based on morphological and immunohistochemical analyses
performed at a reference laboratory, following the World Health
Organization (WHO) criteria [42–44] Thirty-one patients (78%)
had cancer, 17 of whom (55%) showed metastatic disease; the
remaining 9 children (23%) had inflammatory/reactive diseases.
According to histopathological/immunohistochemical diagnosis,
11 patients (12 samples) had neuroblastoma, 3 (4 samples) had
rhabdomyosarcoma, 2 (2 samples) a primitive neuroectodermal
tumor (PNET), 8 (9 samples) had lymphoma, 2 (2 samples) Wilms
tumors, 2 (3 samples) germ cell tumors, and one patient had an
adrenal carcinoma, one a nasopharyngeal carcinoma, and one an
hemangioperycitoma; the other 17 specimens corresponded to 9
reactive samples and 8 samples from patients with neoplastic
diseases which showed no tumor infiltration. The specific origin of
the specimens is detailed in Table S1.
Ethics Statement
The study was approved by the Ethics Committee of the
IPPMG and HSE hospitals and samples were obtained after
informed consent was given by the children and their parents or
guardians, according to the Helsinki Declaration protocol.
Parents/guardians provided their written informed consent to
participate in this study and this written informed consent was
approved by the local ethics committees.
Preparation of Tissue Samples and Body Fluids
Tissue samples free from fat and necrotic tissue (mean weight:
144 mg; range: ,3 to 3,600 mg) were collected at the surgical
unit. They were directly evaluated by an experienced pathologist,
and divided into two contiguous blocks. One block was fixed in
formalin, embedded in paraffin and processed for routine
histopathology, while the other was placed in cold (4uC)
phosphate-buffered saline (PBS; pH = 7.4) for further flow
cytometric analyses. The later sample was weighted, placed in a
Petri dish with PBS containing 1% bovine serum albumin (BSA;
Calbiochem, La Jolla, CA), minced into small pieces (2–4 mm)
with a scalpel blade and mechanically disaggregated with two
sterile needles; afterward, it was filtered through a sterile Filcon
syringe (100 mm pore size) to eliminate cell clumps and debris,
centrifuged (10 min at 540 g) and resuspended in PBS containing
1% BSA at a final concentration of 106 cells/mL. Afterward, the
sample was immediately stained for MFC immunophenotyping.
Bone marrow (BM) and other body fluid samples were stained
either directly or after a centrifugation step (e.g. urine), as
described below.
Multiparameter Flow Cytometry Immunophenotypic
Studies
Each sample was stained with the following combinations of
fluorochrome-conjugated monoclonal antibodies (MAbs) – fluo-
rescein isothiocyanate (FITC)/phycoerythrin (PE)/PE-cyanin7
(PECy7)/peridinin chlorophyll protein-Cy5.5 (PerCP-Cy5.5)/allo-
phycocyanin (APC)/APC-Hilite7 (APC-H7)/pacific blue (PacB)/
pacific orange (PacO) – devoted to simultaneous identification of
tumor cells and normal/reactive B- and T-lymphocytes, mono-
cytes and neutrophils :i) cytoplasmic (Cy) MPO/CyCD79a/
CD19/CD34/CD7/surface membrane (Sm) CD3/CyCD3/
CD45 [45]; ii) CD8-surface membrane immunoglobulin
(SmIg)l/CD56-sIgk/2/CD19+CD4/CD3/2/CD20/CD45 (ori-
entation panel in Table S2). Whenever suspicious tumor cells were
detected following the gating strategy illustrated in figure 1, further
phenotypic characterization of such suspicious tumor cells was
performed with distinct characterization panels depending on the
nature of the cells: non-hematopoietic vs B vs T vs other
hematopoietic cells (Table S2). Staining of cells from solid tissues
or BM, peripheral blood (PB) and other body fluids was performed
as previously described in detail [46,47]. Briefly, the samples (50 ml
per tube) were incubated for 15 min at room temperature in the
dark, in the presence of 3–20 ml of each of the above mentioned
monoclonal antibodies (MAb), according to the recommendations
of the manufacturers. Afterward, 2 ml of FACS lysing solution
(Becton Dickinson) diluted 1:10 (v/v) in distilled water was added,
and the samples were incubated for another 10 min under the
same conditions as those mentioned above, in order to lyse non-
nucleated red cells. Then, cells were centrifuged (5 min at 540 g)
and the cell pellet was washed twice with 4 ml of PBS. Finally, cells
were resuspended in 0.5 ml of PBS. For the evaluation of
cytoplasmatic (Cy) or nuclear (nu) antigens, cells were fixed,
immediately after they were incubated with the MAb directed
against cell surface membrane markers (see above); then, they
were permeabilized and stained with MAb directed against the
cytoplasmic and/or nuclear antigens, using the Fix & Perm
reagent kit (Invitrogen, Carlsbad, CA, USA), strictly following the
recommendations of the manufacturer. For unconjugated MAb,
after incubation with the specific MAbs, a washing step followed
Flow Cytometry in Pediatric Cancer
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by a second incubation step with a FITC-conjugated anti-mouse
IgG reagent (Cytognos SL, Salamanca, Spain), was performed
(15 min) in the dark. In order to confirm the specificity of the
labelings, a negative control with an unlabeled sample was
systematically run in parallel. Stained cells were acquired at low
speed in a FACSCanto II flow cytometer –Becton/Dickinson
Biosciences (BD), San Jose´, CA, USA, - using the FACSDiVa
software (BD). All except two samples, were processed within the
first 4 h after surgery. For data analysis, the INFINICYTTM
software program (Cytognos SL) was used. Antigen expression was
used to identify the different types of cells present in the sample
and each cell population identified was classified as being negative
(2), dim positive (+lo), intermediate positive (+) and strongly
positive (+hi) using arbitrary relative linear mean fluorescence
intensity (MFI) values of 100–102, 102–103, 103–104, . 104,
respectively, depending on the MFI values observed vs baseline
autofluorescence levels found in the control tube; antigen
expression for a given marker was described as being heteroge-
neous, when variable expression levels were detected for that
marker within a cell population.
Exclusion of non-viable tumor cells was based on their lower
forward (FSC) and sideward (SSC) light scatter features; median
cell viability of tissue specimens was of 75%. In 19/33 (57.5%) of
solid tissue samples, parallel staining with propidium iodide (PI,
Sigma,St Louis, MO, USA) was performed to evaluate cell
viability, .90% of the PI-stained dead cells systematically
corresponding to events which were excluded as non-viable cells
in the FSC/SSC gate.
Histological and Immunohistochemical Analyses
Histophatological examination was performed on hematoxilin/
eosin (H&E) stained tissue sections (3 mm). In all samples where
tumor infiltration was suspected and/or detected, tissue sections
were also stained by conventional immunohistochemistry for the
CD99, nuclear (nu)MYOD1, (nu)myogenin, synaptophysin, chro-
mogranin, NSE, LCA, CD20, CD19, Ki67 and CD10 markers.
Stained slides were independently assessed by two experienced
pathologists. For BM, PB and urine samples, conventional
cytological analysis was performed.
Statistical Methods
In order to establish the statistical significance of differences
observed between groups, the Mann-Whitney U test was used
(continuous variables; SPSS software program, version 18.0, SPSS
Inc., Chicago, IL, USA). The number of true-positive (TP;
samples with the presence of a tumor cell population as detected
by both conventional diagnostic techniques and flow cytometry),
true-negative (TN; samples without tumor cell population as
measured by conventional approaches and flow cytometry), false-
positive (FP; samples with the presence of a tumor cell population
by flow cytometry not detected by the reference methods) and false
negative cases (FN; samples with undetectable tumor cells by flow
cytometry but positive by the reference approaches), were
calculated. Sensitivity and specificity were defined as TP/TP+FN
and TN/TN+FP respectively, whereas the positive (PPV) and
negative predictive values (NPV) were calculated as TP/TP+FP
and TN/TN+FN, respectively.
Results
Differential Diagnosis between Reactive/Non-infiltrated
and Tumor/infiltrated Samples
Based on the screening panel (panel 1 in Table S2), 9/52
samples (17%) corresponded to reactive samples; another 8
(15%) samples obtained from cancer patients for disease staging
or monitoring purposes, were also negative for malignancy. All
other samples (n = 35; 68%) showed infiltration by tumor cells.
The overall concordance rate between MFC and conventional
histopathological, immunohistochemical and/or cytological di-
agnostic procedures was of 96% (50/52 samples). In detail, a
100% agreement was attained for the 17 reactive/inflammatory
and non-infiltrated samples, whereas a 94% concordance rate
(33/35 samples) was achieved by MFC for infiltrated tumor
samples. The two tumor samples which were misclassified by
MFC corresponded to samples infiltrated by Hodgkin lympho-
ma cells and an anaplastic lymphoma, respectively. All samples
infiltrated by solid tumors and B- or T-cell lymphomas were
correctly identified (Table 1). Therefore, an overall efficiency of
96% (100% specificity and 94% sensitivity) was reached (PPV of
100% and NPV of 90%). The cellular composition of both
reactive/inflammatory and other non-infiltrated samples is
shown in Table S3, while the distribution of stromal cells
(inflammatory, endothelial and fibroblasts/mesenchymal cells) in
14/26 samples that contained non-hematopoietic solid tumors is
shown in Table S4.
Identification of Lymphoma Versus Non-hematopoietic
Tumor Cells
A total of 35 samples (from 31 patients) contained tumor cells
based on the screening panel (panel 1 in Table S2) and the
characterization panels (panels 2 to 5 in Table S2). From them,
9 corresponded to malignant hematopoietic cells and 26 to non-
hematopoietic solid tumors. In the two false-negative lymphoma
cases, a rich polyclonal lymphocyte infiltrate was observed by
MFC, without a clearly defined tumor cell population. In turn,
all B-cell lymphoma cases (5/5) could be easily distinguished
from pediatric solid tumors with screening panel 1 (Table S2)
by the expression of B-cell markers (CD19+, cyCD79a+, CD22+)
in association with CD45+lo or CD45+, while these markers
were systematically absent in all 26 pediatric solid tumors. With
the B-cell characterization panel (panel 3 in Table S2) three B-
cell lymphoma samples showed surface membrane (Sm)Ig light
chain restriction (2 cases SmIgl
+ and one SmIgk
+) together with
a Tdt+, CD20+hi, CD38+hi, CD10+hi, cyBcl22 immunopheno-
type which is highly characteristic of childhood Burkitt
lymphoma, except for TdT expression. The other two B-cell
tumors presented with a CD45+lo, CD19+, CD202, CD22+,
CD102, CD38+, CD58+, CD81+, CD9+, SmIg
2, CyIgm
2
phenotype compatible with B-cell precursor acute lymphoblastic
lymphoma (BCP-ALL) by both MFC and histopathology. In
turn, 2 T-cell lymphoma samples could be easily distinguished
from both pediatric solid tumors and B-cell lymphomas with the
screening panel (panel 1 in Table S2) based on their CD45+lo,
SmCD3
+lo and CyCD3
+ phenotype; in addition, these cells also
showed a CD4+, CD82, CD1a+, CD99+, CD2+, CD5+, CD27+,
CD71+ and CD81+ phenotypic profile, lacking CD72, CD1172
and B-cell markers once the appropriate screening and
characterization panels (panels 1 and 4 in Table S2, respec-
tively) were used. All 26 non-hematopoietic solid tumors
analyzed were negative for all B and T-cell specific antigens
investigated with the screening panel (panel 1 in Table S2), and
they were CD452. Twenty-two of these later cases (84%)
expressed CD56+, together with variable patterns of expression
of other markers associated with different non-hematopoietic
tissues which were included in the characterization panel for
solid tumors (panel 2 Table S2) as described below.
Flow Cytometry in Pediatric Cancer
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Immunophenotypic Characterization of Non-
Hematopoietic Tumor Cells
Almost half of the non-hematopoietic tumors corresponded to
neuroblastoma (12/26; 46%). They showed a uniform population
of CD452, CD56+, CD9+, CD81hi, GD2+ tumor cells with
heterogeneous expression of CD572/+ and CD58+/++; CD90 was
positive in all but one tumor, whereas CD271 was partially
expressed in only one tumor (Table 2). Interestingly, the only
ganglioneuroblastoma tumor analyzed showed two clearly differ-
ent populations of tumor cells: 39% had an immunophenotype
identical to that of the other neuroblastomas, while the remaining
cells (61%) displayed higher light scatter (FSC and SSC) and
greater expression of CD56, CD81 and CD57. None of the other
markers tested (e.g. CD99, CD38, CD19, CD20, CyCD79a,
CD34, numyogenin, nuMYOD1) was expressed by neuroblastoma
cells. From all tumors, neuroblastoma was the only GD2+hi
neoplasia, at the same time it also showed higher CD56 levels per
cell (Table 2; Figures 1 and 2). Although PNET tumors showed a
phenotype which resembled that of neuroblastoma (CD452,
CD56hi, CD90+, CD9+, CD81+, nuMYOD1
2, numyogenin
2 in
the absence of B-, T- and myeloid-associated markers), they were
negative for GD2, except for one with low expression on a small
tumor population 48%, and showed stronger expression of CD99hi
and CD271hi (Table 2; Figures 1 and 2).
Based on the same screening and characterization panels
(panels 1 and 2 in Table S2, respectively), all four rhabdomyo-
sarcomas (RMS) showed a specific nuMYOD1
hi, numyogenin
hi
phenotype. Moreover, RMS cases were also CD452, CD56+lo,
CD90+ and CD572; two expressed CD81+, CD9+ and CD58+
and one was partially positive for CD99 (40% of tumor cells ), a
phenotypic pattern which was specific for this tumor subtype
(Table 2; Figures 1 and 2).
Figure 1. Immunophenotypic identification and chraracterization of pediatric tumor samples. In panel A, an illustrating example of the
gating strategy and bivariate dot plot combinations used for the identification of CD452 tumor cells, CD452 residual stromal cells (e.g. endothelial
cells and mesenquimal cells) and infiltrating hematopoietic cells (e.g. neutrophils, B and T cells) is shown. In turn, in panels B to J the
immunophenotypic profile of CD452 tumor cells from a neuroblastoma (panels B and H), a PNET (panels C and I) and a rhabdomyossarcoma (panels
D and J) tumor are shown together with representative pictures of the histophathological and immunohistochemical profiles of the same tumors
stained with hematoxilin & eosin plus cromogranin (neuroblastoma cells in panel E), CD99 (PNET cells in panel F) and (nu)myogenin
(rhabdomyossarcoma cells in panel G).
doi:10.1371/journal.pone.0055534.g001
Flow Cytometry in Pediatric Cancer
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The remaining 8 tumor samples corresponded to 5 distinct
tumor subtypes (Wilms tumor, 2 cases; germ cell tumor, 3; adrenal
carcinoma, nasopharyngeal carcinoma and hemangiopericytoma,
one case each). Strong EpCAM expression was restricted to the
two carcinomas, while hemangiopericytoma cells were the only
displaying CD34+hi expression; both groups of tumors systemat-
ically lacked CD45, B- and T-cell markers (Table 2; Figures 1 and
2). In turn, all germ cell tumors presented with a distinct CD452,
CD56+, CD10+, CD382, CD192, CD222, NG2+ phenotype,
except for CD10 and NG2 that were negative in 1/3 cases (Table 2
and Figure 2). Conversely, the two Wilms tumors showed two
clearly distinct (coexisting) tumor cell populations with a common
CD56+ and CD58+, CD452, CD992, GD22, nuMYOD1
2,
numyogenin
2, CD102 and NG22 phenotype, but distinct
reactivity (negative versus positive expression) for CD90, EpCAM
and CD57 (Table 2; Figures 1 and 2).
Overall, these results show that distinct pediatric tumor subtypes
were associated with unique and specific phenotypes. NuMYOD1
and numyogenin expression was restricted to RMS (Figure 1J;
Figure2), CD99 was expressed at significant higher levels in PNET
and a subpopulation of (embryonal) RMS (Figure 1I; Figure 2),
whereas strong reactivity for GD2 was specific for neuroblastoma
(Figure 1H; Figure 2), and a CD34hi CD452 phenotype was
restricted to the hemangiopericytoma case studied (Figure 2).
Other less specific markers such as CD56, CD9, CD57, CD81,
CD99 also contributed to some differential diagnoses, e.g. the
distinction between neuroblastoma and RMS
(CD56,CD57,CD81) and between PNET and both RMS (CD9)
and neuroblastoma (CD99, CD56, CD81 and CD57) (Figure 1I–J;
Figure 2).
Discussion
Pediatric cancer mainly derives from early lymphoid precursors
and embryonic mesenchymal and neuroectodermal precursors,
which may show similar morphological and histopathological
patterns [3,5–7]. Consequently, diagnosis of most pediatric tumors
frequently requires further characterization of the neoplastic cells
on e.g. immunophenotypical/immunocytochemical grounds. In
turn, rapid diagnosis of such cases is crucial, since it directly
influences the treatment decision-making process and patient
outcome [2,3]. Therefore, availability of fast techniques to
precisely screen for the tumor cell lineage and establish the
relevant differential diagnoses, are mostly welcome.
Until now, few studies have been reported which evaluate the
utility of MFC immunophenotyping for the diagnostic screening
and subclassification of pediatric solid tumors [11–13,27–
28,31,35–39,41,48–51] Noteworthy, a relatively low (59%) con-
cordance rate between immunophenotyping of fine-needle aspi-
rated specimens by flow-cytometry and conventional cytological
analyses has been reported, due to low sample cellularity [36].
Interestingly, here we obtained enough viable cells in every sample
analyzed by using mechanical disaggregation procedures of
freshly-obtained and processed samples, supporting the notion
that mechanical disaggregation keeps antigen expression together
with an acceptable cell viability [16–18,52].
Table 1. Comparison between multiparameter flow cytometry (MFC) and histopathology plus immunohistochemistry (IH) as
regards identification of infiltration by neoplastic cells versus normal/reactive cells.
Diagnostic category N. of concordant samples by MFC vs. IH/Total samples (%)
Non-infiltrated samples: 17/17 100
Reactive/inflammatory samples 9/9 100
Other non-infiltrated samples 8/8 100
Infiltrated samples: 33/35 94
Lymphomas: 7/9 78
T-cell precursor LL 2/2 100
B-cell precursor LL 2/2 100
Diffuse large B cell lymphoma 1/1 100
Burkitt lymphoma 2/2 100
Hodgkin lymphoma 0/1 0
Anaplastic lymphoma 0/1 0
Solid Tumors: 26/26 100
Neuroblastoma 12/12 100
- Gaglioneuroblastoma 1/1 100
Rhabdomyosarcoma 4/4 100
Ewing Sarcoma/PNET 2/2 100
Adrenal carcinoma 1/1 100
Nasopharyngeal carcinoma 1/1 100
Hemagiopericytoma 1/1 100
Germ cell tumor 3/3 100
Wilmstumor 2/2 100
Total 50/52 96
All 8 samples were obtained from pediatric cancer patients, but they were all negative for the presence of tumor cells by conventional diagnostic approaches. LL:
lymphoblastic lymphoma; PNET- primitive neuroectodermal tumor.
doi:10.1371/journal.pone.0055534.t001
Flow Cytometry in Pediatric Cancer
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Of note, none of the samples classified as reactive/inflammatory
by cytological/histopatological criteria was misdiagnosed as cancer
by MFC. In turn, all tumor specimens but two rather uncommon
lymphoma samples, were identified as containing tumor by MFC.
The two false negative cases observed could be due to the lack of
specific markers for Reed-Stenberg and anaplastic lymphoma cells
(e.g. CD30) in our screening panel (panel 1 in Table S2) and the
relatively low frequency and/or viability of these cells in single cell
suspensions. Prospective inclusion of additional markers (e.g.
CD30) in the screening panel for the identification of these cells
may potentially overcome this limitation [53,54].
In pediatric patients, MFC has been mainly applied to the study
of PB and BM samples from patients suspicious of suffering from
acute leukemia. Despite this, early studies in neuroblastoma
patients already showed BM infiltration by CD452/CD56+ tumor
cells, in the absence of proteins denoting hematopoietic commit-
ment [29,33]. Because of the relatively high frequency of
metastatic BM involvement in neuroblastoma, this is by far the
non-hematopoietic pediatric tumor mostly studied by MFC.
Indeed, the phenotype of neuroblastoma cells has been recurrent
evaluated in single or multicolor (3- or 4-color) antibody
combinations both in BM and tumor tissue samples [35,48–
51,55]. However, most of these studies were aimed at assessing
minimal residual disease levels in the BM of neuroblastoma
patients, without exploring the utility of immunophenotyping for
the diagnostic screening and differential diagnosis of neuroblasto-
ma vs. other pediatric tumors, as done here.
From all markers evaluated so far in pediatric solid tumors,
CD56 (NCAM) has been most frequently investigated [31–34].
Interestingly, CD56 is expressed by most pediatric solid tumors
[37–39,51], as also found in our cases. However, the amount of
CD56 expression largely varied among different tumor subtypes.
Neuroblastoma and PNET were those tumors which displayed the
highest CD56 levels, supporting the utility of CD56 both to
discriminate non-hematopoietic vs. hematopoietic neoplasms
[31,34], and for the differential diagnosis between distinct subtypes
of CD452 non-hematopoietic pediatric solid tumors. Similarly,
several studies have evaluated the utility of CD81 and CD9
(together with CD452 and CD56+), for the discrimination
between neuroblastoma cells and BM hematopoietic cells, for
staging purposes [13,48–49,55], without extending such analysis to
other subtypes of pediatric solid tumors. Among our cases, CD81
and CD9 showed a variable and heterogeneous pattern of
expression with limited utility as individual markers, in the
differential diagnosis between neuroblastoma and other pediatric
tumors. However, once combined with other molecules, CD81
Figure 2. Pattern of expression of individual immunophenotypic markers in distinct diagnostic categories of pediatric solid
tumors. Panel A: Heat map summarizing the intensity and pattern of expression of different markers in distinct diagnostic subtypes of pediatric solid
tumors based on mean fluorescent intensity per/cell level. Panel B: Comparison of the mean fluorescent intensity expression of individual markers
per/cell in different WHO subtypes of pediatric solid tumors. Boxes extend from the 25th to 75th percentiles, the lines in the middle represent median
values while horizontal lines correspond to 95% confidence intervals.
doi:10.1371/journal.pone.0055534.g002
Flow Cytometry in Pediatric Cancer
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contributed to the discrimination of neuroblastoma and PNET.
Despite this, GD2 and CD271 were the two most useful markers
to differentiate between neuroblastoma (GD2+hi CD2712/lo) and
PNET (GD22/lo CD271+hi). Overall, these results support the
notion that CD271hi expression identified on PNET may be
associated with the mesenchymal stem cell origin of these tumors
[56]. Interestingly, in the only neuroblastoma patient that showed
CD2712/+lo tumor cells, CD271 expression was restricted to the
primary tumor, while negative in metastatic BM cells; this could
potentially be due to a different degree of tumor cell maturation at
both sites, absence of CD271 being associated with a more
immature and aggressive tumor behavior [57–58]. Of note, CD99
was also highly-expressed in PNET, while typically negative in the
other tumors, suggesting that in addition to CD271, CD99 may
also contribute to the diagnosis of PNET.
Few MFC immunophenotypic studies of RMS have been
reported so far. In line with our observations such studies showed
that RMS cells typically display a CD452, CD56+, CD90+,
numyogenin
+ phenotype with variable expression of CD57,
desmin, vimentin and CD99 [31,36,39,41]. Unfortunately, in
these studies, these and other markers (e.g. nuMYOD1) have not
been systematically investigated in other non-RMS tumors. In line
with previous immunohistochemical studies [40,59], in our series
both numyogenin and nuMYOD1 emerged as specific for RMS
cells.
Differential diagnosis of pediatric small round cell tumors
(SRCT) with respect to both Wilms tumor and non-Hodgkin
lymphoma, frequently remains a challenge. Here, we clearly show
that tumor cells from these later two entities can be clearly
discriminated from other SRCT on immunophenotypic grounds.
Thus, Wilms tumor was the only pediatric cancer subtype which
consisted of two coexisting tumor cell populations, with distinct
immunophenotypes: CD452 CD56+ EpCAM+ CD902 vs. CD452
CD56+ CD90+ EpCAM2. These observations are in line with the
reported coexistence of epithelial (e.g. EpCAM+, CD902) and
mesenchymal (EpCAM2, CD90+) cell components in Wilms
tumors by histopathology [60–61]. In turn, childhood carcinomas
are extremely rare neoplasms whose immunophenotype has not
been previously characterized by MFC. Here we showed high
expression of EpCAM, CD56, CD58 and CD90 by flow
cytometry in two pediatric carcinomas (an adrenal carcinoma
and a nasopharyngeal carcinoma). Since all other non-carcinoma
tumor cell samples (except one subset of tumor cells in the Wilms
tumors) were negative for EpCAM, this marker could also be
potentially useful for the diagnosis of this subtype of pediatric
tumors, particularly if combined with CD90.
In summary, our results indicate that MFC is a useful
complementary tool for fast diagnostic screening and classification
of pediatric cancer. Combined assessment of CD45, CD56, CD81,
CD99, EpCAM, GD2, nuMYOD, numyogenin and CD271,
together with other specific B-cell (e.g. CD19) and T-cell (e.g.
CyCD3) markers, emerges as providing particularly useful infor-
mation for such purpose.
Supporting Information
Table S1 Results expressed as number of patients or samples
and *median values and range between brackets. NA: not
applicable. **Among the non-neoplastic samples, 9 reactive/
inflammatory samples and 8 non-infiltrated samples from patients
with cancer in another localization, were analyzed. §In 6 cases, a
tumor mass plus sample(s) from another site were simultaneously
analyzed (tumor mass plus BM in 2 cases; tumor mass plus urine in
2 cases; tumor mass plus ascitic fluid in one case; tumor mass plus
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BM and PB, one case). In five cases, the primary site was not
accessed because the risk of the procedure and only BM was
analyzed.
&
In one case, tumor masses plus BM and PB were
simultaneouslyanalyzed. In two cases the primary site was not
accessed because the risk of the procedure, and only BM was
analyzed. ‘In one case, a cervical lymph node plus PB were
simultaneouslyanalyzed.
Q
In two cases, a tumor mass plus BM
were simultaneously analyzed.
(DOC)
Table S2 For each Antibody, the marker/CD marker (clone and
commercial source) are displayed. BD: Becton-Dickinson Biosci-
ences (San Jose´, CA, USA). Beckman Coulter (Brea, CA, USA)
CA, USA). Cytognos Cytognos (Salamanca, Spain). Dako
(Glostrup, Denmark). Invitrogen (Carlsbad, CA, USA). Exbio
(Prague, Czech Republic) Miltenyi Biotec (Cologne, Germany) e
Biolegend,CA, USA) *EuroFlow (San Diego,CA,USA) *EuroFlow
ALOT tube [45].
(DOC)
Table S3 Results are expressed as mean percentage of cells
6one standard deviation and range between brackets. *One
sample with inflammatory bowel disease had a subpopulation of
32% CD452/CD562/Epcam+hi identified as normal/residual
epithelial cells. The expression of EpCAM in these cells was much
stronger than that found in carcinoma cells with a pattern
resembling that of normal epithelial cells.
(DOC)
Table S4 Results expressed as median (range) percentage of cells
from the whole sample cellularity, except for those groups for
which only one case was studied*One sample was from a lymph
node infiltrated by neuroblastoma cells 1 One sample was a face
tumor with massive infiltration by inflammatory cells.
(DOC)
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